Aethlon Medical, Inc. (NASDAQ:AEMD) Sees Large Growth in Short Interest

Aethlon Medical, Inc. (NASDAQ:AEMD) was the recipient of a significant increase in short interest in the month of May. As of May 15th, there was short interest totaling 28,844 shares, an increase of 105.3% from the April 30th total of 14,050 shares. Approximately 1.9% of the company’s shares are sold short. Based on an average daily trading volume, of 59,037 shares, the short-interest ratio is currently 0.5 days.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Aethlon Medical in a report on Monday, April 20th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Aethlon Medical currently has a consensus rating of “Reduce”.

Aethlon Medical Price Performance

Shares of NASDAQ:AEMD opened at $2.21 on Wednesday. Aethlon Medical has a 1 year low of $1.36 and a 1 year high of $29.88. The company has a market cap of $3.47 million, a PE ratio of -0.15 and a beta of 1.49. The stock’s 50-day moving average is $2.25 and its 200 day moving average is $2.60.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aethlon Medical stock. Citadel Advisors LLC bought a new position in shares of Aethlon Medical, Inc. (NASDAQ:AEMD) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned 36.57% of Aethlon Medical as of its most recent filing with the Securities and Exchange Commission. 1.99% of the stock is owned by institutional investors and hedge funds.

Aethlon Medical Company Profile

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical?stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life?threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.